Inflammation and cancer, the mastocytoma P815 tumor model revisited: Triggering of macrophage activation in vivo with pro‐tumorigenic consequences
- 17 July 2002
- journal article
- research article
- Published by Wiley in International Journal of Cancer
- Vol. 100 (5) , 571-579
- https://doi.org/10.1002/ijc.10519
Abstract
Subcutaneous in vivo injections of cells of the mastocytoma line P815 in syngenic DBA/2 mice induce locally fast growing solid tumors. These have been used extensively as a cancer model to analyze and manipulate the relationship between tumor cells and host's immune defenses. We report that progression of P815 tumors in vivo was accompanied by a burst (Days 5–7) of local inflammatory cells recruitment and angiogenesis observed histologically, corroborated in vivo by MRI with gadolinium, overtranscription of macrophage activation marker genes, secretion of TNF-α by regional lymph node cells and concomitant systemic inflammation. No substantial overtranscriptions of either VEGF or IL-10 or TGF-β genes were observed. Induction of COX-2 gene was a late event. To establish a possible relationship between the tumor-induced local, regional and systemic increase of pro-inflammatory mediators and progression of tumors in vivo, we carried out experiments deliberately modulating the inflammatory status of the recipient animals. Pretreatment of recipient animals by i.p. injection of thioglycolate accelerated P815 tumor growth. At the opposite, treatment of mice with either a COX-1 + COX-2 inhibitor (aspirin, 1 mg/day/mouse) or a specific COX-2 inhibitor (celecoxib, 0.13 mg/day/mouse) for 2 weeks after injection of tumor cells, significantly reduced the size and growth rate of tumors compared to control mice. Experiments carried out in vitro indicated that peritoneal macrophages from untreated animals were strongly activated by live P815 cells and by P815 membrane preparations. The tumor-induced inflammatory reaction could establish a local micro environment favoring tumor progression. The P815 tumor model might be helpful to recognize important factors controlling host/tumor relationship.Keywords
This publication has 45 references indexed in Scilit:
- The Effect of Celecoxib, a Cyclooxygenase-2 Inhibitor, in Familial Adenomatous PolyposisNew England Journal of Medicine, 2000
- Is cyclooxygenase-2 the alpha and the omega in cancer?Journal of Clinical Investigation, 2000
- The effect of non-steroidal anti-inflammatory drugs on human colorectal cancer cellsEuropean Journal Of Cancer, 2000
- Sulindac Inhibits Activation of the NF-κB PathwayJournal of Biological Chemistry, 1999
- Aspirin prevents tumors in a murine model of familial adenomatous polyposisSurgery, 1998
- Experimental gene therapy of cancer using tumor cells engineered to secrete interleukin‐13European Journal of Immunology, 1995
- Cytokine gene transfer in tumor inhibition and tumor therapy: where are we now?Immunology Today, 1994
- The gene coding for a major tumor rejection antigen of tumor P815 is identical to the normal gene of syngeneic DBA/2 mice.The Journal of Experimental Medicine, 1991
- Interleukin 2‐dependent activation of tumor‐specific cytotoxic T lymphocytes in vivoEuropean Journal of Immunology, 1991
- Sequential measurement of the murine acute-phase protein serum amyloid P component (SAP) as an indicator of graft-versus-host disease following allogeneic bone marrow transplantation in miceClinical and Experimental Immunology, 1990